Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | CMA1 | P23946 | 7/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280077 | 0.89 | HDAC8 (0.45) | HDAC8ELANEOPRM1OPRK1KMT2A | |
| SCHEMBL25496865 | 0.89 | HDAC8 (0.45) | HDAC8ELANEOPRM1OPRK1KMT2A | |
| SCHEMBL5203085 | 0.89 | HDAC8 (0.51) | HDAC8CTSKCTSLCTSBCTSS | |
| SCHEMBL3601919 | 0.83 | CNR2 (0.39) | HDAC8OPRM1OPRK1 | |
| SCHEMBL8312588 | 0.82 | CTSK (0.44) | HDAC8CTSKCTSLCTSBELANE | |
| SCHEMBL13560013 | 0.82 | HDAC8 (0.43) | HDAC8CTSKCTSLCTSBELANE | |
| SCHEMBL22169449 | 0.81 | CTSK (0.50) | HDAC8CTSKCTSLCTSBELANE | |
| SCHEMBL3611500 | 0.81 | CTSK (0.50) | HDAC8CTSKCTSLCTSBELANE | |
| SCHEMBL5203233 | 0.79 | PIN1 (0.54) | HDAC8CTSKCTSLCTSBELANE | |
| SCHEMBL8143604 | 0.79 | CMA1 (0.53) | CTSKCTSLCTSBELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | HDAC8 2170/4885CTSK 170/4885CTSL 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.